# Cancer Drug Price Cuts Leave Costly Brands Untouched

> Price cuts for cancer drugs hit generics but top brands remain unchanged.
- Title: Cancer Drug Price Cuts Leave Costly Brands Untouched
- Summary: Price cuts for cancer drugs hit generics but top brands remain unchanged. Price cuts for 137 cancer drugs cap trade margins at 30% but key patented…
- Keywords: keytruda, opdyta, tagrisso, imjudo, nppa, cancer drugs, price cuts, patented drugs, generic drugs, trade margins, Cancer, Drug
- Source: The Economic Times — https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cancer-drug-price-cuts-leave-costly-brands-untouched/articleshow/135244832.cms
- Author: ET Bureau
- Published: 2026-10-27T19:11:00+00:00
- Read time: 1 min
- Topics: keytruda, opdyta, tagrisso, imjudo, nppa, cancer drugs, price cuts, patented drugs, generic drugs, trade margins
## Price Cuts Effective November 9
Prices of several widely used cancer drugs fall sharply from November 9 after NPPA revision.
## Top Patented Drugs Unchanged
Keytruda 100 mg injections remain at ₹2,16,500, Imjudo 300 mg at ₹4,17,522, and Opdyta 100 mg at ₹1,09,450.
## Generic Drugs See Steep Price Drops
Sunitinib capsules drop from ₹889 to ₹285.69, olaparib tablets from ₹15,398 to ₹2,695, and palbociclib capsules from ₹24,505 to ₹2,068.
## NPPA Caps Trade Margins at 30%
NPPA revised prices for 137 cancer drugs with trade margins capped at 30% effective November 9.
## Patient Assistance Programs Offer Alternative
Private hospitals may lower effective prices through patient assistance programs for patented cancer drugs.
## Key takeaway

Price cuts for 137 cancer drugs cap trade margins at 30% but key patented treatments like Keytruda stay at high prices.